The status of antimicrobial resistance of Helicobacter pylori in eastern Europe

Boyanova, Lyudmila; Mentis, Αndreas; Gubina, Marija; Rozynek, E; Gościniak, Grażyna; Kalenić, Smilja; Goral, V. M.; Kupčinskas, Limas; Kantarçeken, Bülent; Aydın, Ahmet; Archimandritis, A; Dzierżanowska, D; Včev, Aleksandar; Ivanova, K.; Marina, M.; Mitov, Ivan; Petrov, Peter K.; Özden, Ali; Popova, M

doi:10.1046/j.1469-0691.2002.00435.x

Cited by 74 publications

(54 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The standard treatment for H. pylori infections has depended on antibiotics in combination with proton pump inhibitors (3). Despite the efficacy of such treatment for the resolution of gastritis and a decrease in the relapse rate of duodenal ulcers, the resistance of H. pylori to antibiotics is increasing (5). Therefore, there is a need for development of new strategies to control H. pylori infection and disease.…”

mentioning

confidence: 99%

Orally Administered CpG Oligodeoxynucleotide Induces Production of CXC and CC Chemokines in the Gastric Mucosa and Suppresses Bacterial Colonization in a Mouse Model ofHelicobacter pyloriInfection

et al. 2003

View full text Add to dashboard Cite

Bacterial DNA and unmethylated CpG oligodeoxynucleotides (CpG ODN) are known to be potent stimulators of the innate immune system in vitro and in vivo. We therefore investigated if oral administration of CpG ODN could enhance innate immunity in the gastric mucosa and control the extent of Helicobacter pylori infection in mice. Intragastric administration of a single dose of CpG ODN significantly increased local production of the CC chemokines macrophage inflammatory protein 1␣ (MIP-1␣), MIP-1␤, and RANTES and the CXC chemokine gamma interferon-inducible protein 10 in the stomach and/or the small intestine. Importantly, intragastric administration of CpG ODN to mice with an already established H. pylori infection, in the absence of any coadministered antigen, was found to reduce the bacterial load in the stomach compared to the load in H. pylori-infected control mice, while similar administration of non-CpG ODN had no effect on the bacterial load. The reduction in the bacterial numbers in the stomachs of mice treated with CpG ODN was associated with enhanced infiltration of immune cells and increased RANTES production in the gastric mucosa compared to the infiltration of immune cells and RANTES production in H. pylori-infected control animals. These findings suggest that intragastric administration of CpG ODN without antigen codelivery may represent a valuable strategy for induction of innate immunity against H. pylori infection.

show abstract

mentioning

confidence: 99%

Orally Administered CpG Oligodeoxynucleotide Induces Production of CXC and CC Chemokines in the Gastric Mucosa and Suppresses Bacterial Colonization in a Mouse Model ofHelicobacter pyloriInfection

et al. 2003

View full text Add to dashboard Cite

show abstract

“…AMX는 내 성 판정기준이 정립되어 있지 않아서 0.5에서 8μg/mL까지의 기준을 각각 적용하였다 [7,11,[14][15][16]. Dotted line and dotdash lines were for the breakpoint of 2μg/mL and 0.5μg/mL, respectively.…”

Section: 감수성 판정기준 설정unclassified

Clarithromycin and Amoxicillin Susceptibility Testing ofHelicobacter pyloriby Disk Diffusion Method

Sung

Kang

Lee

et al. 2009

Korean J Clin Microbiol

View full text Add to dashboard Cite

Background: CLSI provides a guideline only for a agar dilution method of testing clarithromycin susceptibility for Helicobacter pylori. This study was to evaluate a disk diffusion method for clarithromycin and amoxicillin. Methods: One hundred and forty clinical isolates of H. pylori isolated from May 2005 to May 2007 were tested by the CLSI agar dilution method and a disk diffusion method using 2μg (2CLR) and 15μg (15CLR) clarithromycin disks and 2μg (2AMX) and 10μg (10AMX) amoxicillin disks. The interpretation criteria used for the disk diffusion method were established by linear regression and error rate-bounded method for disk diffusion zone of inhibition (DDZ) compared to MIC. Results: Resistance and intermediate rates to clarithromycin were 21.4% and 1.4%, respectively. A number of isolates with MIC 0.5, 1, and 2 (μg/mL) to amoxicillin were 7, 2, and 1, respectively. For 2CLR and 15CLR, the coefficients of determination (R

show abstract

“…Therefore, the ideal treatment for H. pylori infection is still far from being reached and more effective and better tolerated alternative regimens are needed (16). Conversely, resistance to fluoroquinolones remains a rare occurrence, varying from 3.3% in France (17), 4.7% in the Netherlands (18), 3.9% in five Eastern European countries (19), and a high resistance rate of 20.9% in Portugal (20). And the data on the primary resistance to moxifloxicin are limited.…”

Section: Introductionmentioning

confidence: 99%

Moxifloxacin-Based Triple Therapy Versus Clarithromycin-Based Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials

Wang

Yang

et al. 2009

Intern. Med.

View full text Add to dashboard Cite

Background Moxifloxacin-based (RR, 1.13; 95% CI, 1.01, 1.27; P=0.04). There were no statistically significant difference in the overall side effects (RR, 0.61; 95% CI, 0.25, 1.48; P<0.28). Conclusions Moxifloxacin-based triple therapy is more effective and does not increase the incidence of overall side effects compared to clarithromycin-based triple therapy in the treatment of H. pylori infection.

show abstract

The status of antimicrobial resistance of Helicobacter pylori in eastern Europe

Cited by 74 publications

References 19 publications

Orally Administered CpG Oligodeoxynucleotide Induces Production of CXC and CC Chemokines in the Gastric Mucosa and Suppresses Bacterial Colonization in a Mouse Model ofHelicobacter pyloriInfection

Orally Administered CpG Oligodeoxynucleotide Induces Production of CXC and CC Chemokines in the Gastric Mucosa and Suppresses Bacterial Colonization in a Mouse Model ofHelicobacter pyloriInfection

Clarithromycin and Amoxicillin Susceptibility Testing ofHelicobacter pyloriby Disk Diffusion Method

Moxifloxacin-Based Triple Therapy Versus Clarithromycin-Based Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About